Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
Doc2UK is a specialist UK medical recruitment and candidate support platform. Based in London, the platform places qualified doctors in the National Health Scheme (NHS) roles around the United Kingdom. The British Medical Association (2018) reported that patient care is at risk due to a critical shortage of doctors across multiple medical disciplines. At present, the UK only has 24 medical schools to fill this gap, whilst India, in comparison, has 468 medical schools, with 68,000 doctors graduating each year. Moreover, uncertainty about the status of EU nationals after Brexit, changes to immigration policies, and the impact of changing language testing requirements for international nurses have made this crisis worse. This situation necessitates recruiting doctors from overseas an important endeavour. This is where Doc2UK aims to become a key player and ensure that lack of medical personnel doesn't disrupt any medical services. The company is seeking an investment of up to £300,000 which will be used to develop the platform with more features, expand the team, marketing and sales.
days to go:
Expired
investment:
Withheld
For Good Causes turn Loyalty points into donations for charities, giving people a new way to give to causes closest to their hearts. Brands are given a while new CSR opportunity and charities are given much-needed funding. Research has shown their is over £7bn unused rewards in the UK, values which could be donated.
days to go:
Expired
investment:
£292,220
A financial management software application for consumers to view everything from credit files and bank accounts, to vouchers and cashbacks. Score Genius aims to launch an Alpha version of their product at the end of 2018, with a public release planned for March 2019. The service will offer users the ability to monitor their credit files and perform transactions on their bank accounts and credits, as Open Banking will be integrated into the platform.
Score Genius is near completion of negotiations with large technological partners. Investments will used to market the platform and further develop features and functions, ready for the public release in 2019. Revenue streams will be comprised of advertisements, redeeming vouchers and users looking to switch their energy.
days to go:
Expired
investment:
£144,920
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
